Nephrocare Health Services
add_icon

Nephrocare Health Services

639.55
-20.00
(-3.03%)
Market Cap
6,417.29 Cr
PE Ratio
85.72
Volume
99,957.00
Day High - Low
666.70 - 630.20
52W High-Low
769.75 - 446.00
ann
There are new updates from the company1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
6,417.29 Cr
EPS
8.48
PE Ratio
85.72
PB Ratio
5.90
Book Value
111.27
EBITDA
223.87
Dividend Yield
0.00 %
Return on Equity
11.49
Debt to Equity
0.53
Analyst Rating and Forecast
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Nephrocare Health Services' subsidiary acquired dialysis center assets in the Philippines for PhP 151.6M to expand operations.
positive
Nephrocare to Acquire Philippines Dialysis Center for PH₱ 80,640,000Jun 23, 2026
Nephrocare Health Services agrees to acquire a dialysis center in the Philippines for PH₱ 80,640,000 through its subsidiary Nephrocare Health Care Services, Philippines Inc.
neutral
Nephrocare Health Services Ltd approved ESOP 2026 covering 20,06,814 options and INR 70 Cr collateral for its Saudi subsidiary. The ESOP represents 2% of paid-up capital.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,653.50
#1 27,718.91
55.18
#1 2,864.20
12.11
#1 510
-14.98
54.02
1,326.00
13,644.11
79.43
814.20
16.36
182
37.25
51.54
549.35
11,389.55
61.33
1,645.85
22.25
185
74.66
53.12
521.70
8,303.65
51.98
846.00
20.48
163
#1 125.46
47.89
639.55
#5 6,417.29
#9 85.72
#4 998.85
#2 29.74
#7 62
#7 22.09
41.11
544.80
1,767.26
17.68
772.77
4.05
106
101.45
47.54
262.60
1,367.64
44.67
310.41
21.30
34
-13.89
39.07
611.25
1,194.56
18.09
498.18
#1 237.06
69
65.45
48.51
314.65
1,000.92
-699.33
1,319.27
12.68
-3
-173.86
54.09
1,166.20
1,000.91
#1 16.77
141.92
27.17
61
22.50
44.60
Growth Rate
Revenue Growth
29.74 %
Net Income Growth
-7.73 %
Cash Flow Change
87.26 %
ROE
35.34 %
ROCE
60.40 %
EBITDA Margin (Avg.)
-6.81 %

Quarterly Financial Results

Quarterly Financials
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
203
223
234
250
263
277
Expenses
153
168
180
182
199
215
EBITDA
50
55
54
68
64
62
Operating Profit %
22 %
23 %
21 %
26 %
23 %
19 %
Depreciation
18
19
20
23
22
26
Interest
5
6
6
45
6
3
Profit Before Tax
26
30
29
-1
36
33
Tax
6
5
5
9
4
3
Net Profit
20
25
24
-10
32
30
EPS in ₹
2.47
3.05
13.10
-1.12
3.43
3.03

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
2026
Total Assets
428
571
666
806
997
1,471
Fixed Assets
192
205
239
356
396
436
Current Assets
178
285
324
390
545
839
Capital Work in Progress
2
43
34
1
6
6
Investments
0
0
0
0
51
33
Other Assets
234
322
393
450
544
0
Total Equity & Liabilities
428
571
666
806
997
1,471
Current Liabilities
94
94
175
243
284
299
Non Current Liabilities
75
81
103
150
129
55
Total Equity
259
396
389
414
584
1,117
Reserve & Surplus
245
387
384
409
579
1,096
Share Capital
4
5
5
2
2
20

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
Net Cash Flow
5
6
-5
47
65
Investing Activities
-62
-130
-76
-52
-125
Operating Activities
32
14
11
72
135
Financing Activities
36
121
60
27
54

Share Holding

% Holding
Jul 2025
Dec 2025
Mar 2026
Promoter
79.05 %
63.85 %
63.85 %
FIIs
0.00 %
9.30 %
9.94 %
DIIs
0.00 %
8.10 %
8.65 %
Government
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
5.92 %
5.08 %
Others
20.94 %
12.82 %
12.48 %
No of Share Holders
65
36
43,409

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
10 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
10 Feb 2026 512.90 527.50
19 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
19 May 2026 529.25 642.10

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20181 day ago
Issuance Of Standby Letter Of Credit Facilities2 days ago
Issuance Of Corporate Guarantee And Standby Letter Of Credit FacilitiesJun 25, 2026
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJun 25, 2026
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJun 23, 2026
Disclosure Under Regulation 30 - Approval Of Nephroplus Employee Stock Option Scheme 2026.Jun 22, 2026
Closure of Trading WindowJun 19, 2026
Cancellation Of Scheduled Analyst / Institutional Investor MeetingsJun 17, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 11, 2026
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJun 10, 2026
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJun 04, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2026
Announcement under Regulation 30 (LODR)-AcquisitionMay 26, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2026
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMay 26, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2026
Re-Appointment Of Internal AuditorMay 19, 2026
Issuance Of Corporate GuaranteeMay 19, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2026
Board Meeting Outcome for Outcome Of The Board Meeting Held On May 19 2026May 19, 2026
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2026
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMay 12, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 04, 2026
Board Meeting Intimation for Intimation Of Board Meeting For Considering Audited Financial Results Of The Company.May 04, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementApr 03, 2026
Announcement Under Regulation 30 (LODR)- Disclosure Of Litigation Filed By The CompanyApr 02, 2026
Closure of Trading WindowMar 25, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 16, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2026
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsFeb 12, 2026
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 12, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 11, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 10, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2026
Board Meeting Outcome for Outcome Of The Board Meeting Held On February 10 2026Feb 10, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 07, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 30, 2026
Board Meeting Intimation for Considering And Approving Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended 31St December 2025.Jan 30, 2026
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJan 27, 2026
Issuance Of Corporate Guarantee For And On Behalf Of Nephrocare Health Care Services Philippines Inc. Philippines Step-Down Wholly-Owned Subsidiary Not Exceeding USD 6.00 Million. Jan 15, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 15, 2026

Technical Indicators

RSI(14)
Neutral
46.00
ATR(14)
Less Volatile
29.31
STOCH(9,6)
Neutral
27.44
STOCH RSI(14)
Oversold
11.00
MACD(12,26)
Bearish
-8.91
ADX(14)
Weak Trend
20.94
UO(9)
Bearish
47.11
ROC(12)
Downtrend And Accelerating
-8.82
WillR(14)
Oversold
-89.13